DelveInsight’s, “Methicillin-Resistant Staphylococcus Aureus Infections Pipeline Insight 2023” report provides comprehensive insights about 25+ companies and 27+ pipeline drugs in Methicillin-Resistant Staphylococcus Aureus Infections pipeline landscape. It covers the Methicillin Resistant Staphylococcus Aureus pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Methicillin Resistant Staphylococcus Aureus pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Methicillin Resistant Staphylococcus Aureus Pipeline Report

• DelveInsight’s Methicillin Resistant Staphylococcus Aureus pipeline report depicts a robust space with 25+ active players working to develop 27+ pipeline therapies for Methicillin Resistant Staphylococcus Aureus treatment.
• The leading companies working in the Methicillin Resistant Staphylococcus Aureus Market include Trellis Bioscience, LegoChem Biosciences, Aptorum Group, ContraFect, Crystalgenomics, Cellics Therapeutics, MicuRx, Oxford Antibiotic Group, Destiny Pharma, TSRL, Inc., TAXIS Pharmaceuticals, Basilea Pharmaceutica, Helperby Therapeutics, Akagera Medicines, Histogen, Alphamab Co. Ltd, Biocidium Pharmaceuticals, and others.
• Promising Methicillin Resistant Staphylococcus Aureus Pipeline Therapies in the various stages of development include Linezolid (Zyvox), Vancomycin, Ceftaroline fosamil, Linezolid, Telavancin, Tigecycline, and others.
• March 2023: Henry M. Jackson Foundation for the Advancement of Military Medicine announced a study of Phase 1 & 2 clinical trials for Monovalent rAT. This study involves the use of investigational vaccines. A vaccine is a medicine that causes the body to make antibodies. Antibodies help destroy foreign substances that enter the body. The purpose of this study is to find the right dose of a new vaccine that is safe and produces a good immune response (how well your body recognizes and defends itself against harmful foreign substances). There are two Staphylococcus aureus toxoids (components or antigens) under investigation in this study; one of them is a protein known as rAT and the other is a protein known as rLukS-PV. They are being developed to see if they are effective at preventing infections caused by the bacteria Staphylococcus aureus.
• July 2023: AbbVie announced a study of Phase 3 clinical trials for Dalbavancin single dose. To determine the safety and descriptive efficacy of dalbavancin for the treatment of acute bacterial skin and skin structure infections in children, aged birth to 17 years (inclusive), known or suspected to be caused by susceptible Gram-positive organisms, including methicillin-resistant strains of Staphylococcus aureus.

 

Request a sample and discover the recent advances in Methicillin Resistant Staphylococcus Aureus Treatment Drugs @ Methicillin Resistant Staphylococcus Aureus Pipeline Report

 

In the Methicillin Resistant Staphylococcus Aureus pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Methicillin-Resistant Staphylococcus Aureus Infections collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Methicillin Resistant Staphylococcus Aureus Overview

Methicillin-resistant Staphylococcus aureus (MRSA) is one of the most successful modern pathogens. The same organism that lives as a commensal and is transmitted in both health-care and community settings is also a leading cause of bacteraemia, endocarditis, skin and soft tissue infections, bone and joint infections and hospital-acquired infections.

 

Find out more about Methicillin Resistant Staphylococcus Aureus Therapeutics Assessment @ Methicillin Resistant Staphylococcus Aureus Preclinical and Discovery Stage Products

 

Methicillin Resistant Staphylococcus Aureus Emerging Drugs Profile

• HY-004B8b: Helperby Therapeutics
• TRL1068: Trellis Bioscience
• Delpazolid (LCB01-0371): LegoChem Biosciences

 

Methicillin Resistant Staphylococcus Aureus Pipeline Therapeutics Assessment

There are approx. 25+ key companies which are developing the Methicillin-Resistant Staphylococcus Aureus Infections therapies. The Methicillin-Resistant Staphylococcus Aureus Infections companies which have their Methicillin-Resistant Staphylococcus Aureus Infections drug candidates in the most advanced stage, i.e. phase II include, Helperby Therapeutics.

 

DelveInsight’s Methicillin-Resistant Staphylococcus Aureus Infections Pipeline Report covers around 27+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

 

Methicillin-Resistant Staphylococcus Aureus Infections pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• intravenous
• Subcutaneous
• Topical.
• Molecule Type

 

Methicillin-Resistant Staphylococcus Aureus Infections Pipeline Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

 

Learn more about the emerging Methicillin Resistant Staphylococcus Aureus Pipeline Therapies @ Methicillin Resistant Staphylococcus Aureus Clinical Trials Assessment

 

Scope of the Methicillin Resistant Staphylococcus Aureus Pipeline Report

• Coverage- Global
• Methicillin Resistant Staphylococcus Aureus Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Methicillin Resistant Staphylococcus Aureus Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Methicillin Resistant Staphylococcus Aureus Companies- Trellis Bioscience, LegoChem Biosciences, Aptorum Group, ContraFect, Crystalgenomics, Cellics Therapeutics, MicuRx, Oxford Antibiotic Group, Destiny Pharma, TSRL, Inc., TAXIS Pharmaceuticals, Basilea Pharmaceutica, Helperby Therapeutics, Akagera Medicines, Histogen, Alphamab Co. Ltd, Biocidium Pharmaceuticals, and others.
• Methicillin Resistant Staphylococcus Aureus Pipeline Therapies- Linezolid (Zyvox), Vancomycin, Ceftaroline fosamil, Linezolid, Telavancin, Tigecycline, and others.

 

Dive deep into rich insights for new drugs for Methicillin Resistant Staphylococcus Aureus Treatment, Visit @ Methicillin Resistant Staphylococcus Aureus Market Drivers and Barriers, and Future Perspective

 

Table of Content

1. Introduction
2. Executive Summary
3. Methicillin-Resistant Staphylococcus Aureus Infections: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Methicillin-Resistant Staphylococcus Aureus Infections – DelveInsight’s Analytical Perspective
7. Mid Stage Products (Phase II)
8. HY-004: Helperby therapeutics
9. Drug profiles in the detailed report…..
10. Early Stage Products (Phase I)
11. TRL1068: Trellis Bioscience
12. Drug profiles in the detailed report…..
13. Preclinical and Discovery Stage Products
14. EVX B1: Evaxion Biotech
15. Drug profiles in the detailed report…..
16. Inactive Products
17. Methicillin-Resistant Staphylococcus Aureus Infections Key Companies
18. Methicillin-Resistant Staphylococcus Aureus Infections Key Products
19. Methicillin-Resistant Staphylococcus Aureus Infections- Unmet Needs
20. Methicillin-Resistant Staphylococcus Aureus Infections- Market Drivers and Barriers
21. Methicillin-Resistant Staphylococcus Aureus Infections- Future Perspectives and Conclusion
22. Methicillin-Resistant Staphylococcus Aureus Infections Analyst Views
23. Methicillin-Resistant Staphylococcus Aureus Infections Key Companies
24. Appendix

 

For further information on the Methicillin Resistant Staphylococcus Aureus Pipeline therapeutics, reach out to Methicillin Resistant Staphylococcus Aureus Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting